Nontuberculous Mycobacterial Infection Market Report 2026

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $14.96 billion in 2025 to $15.87 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to high incidence of pulmonary infections, limited effective therapies, delayed diagnosis of nontuberculous mycobacteria, reliance on conventional antibiotic regimens, low awareness among clinicians.

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $21.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rising adoption of macrolide and rifampin combination therapies, increasing availability of aminoglycosides, growth of personalized treatment approaches, expansion of hospital and specialty pharmacy networks, development of ai-enabled monitoring and diagnostic tools. Major trends in the forecast period include rising adoption of macrolide and rifampin therapies, increasing use of aminoglycoside-based treatments, growing implementation of combination drug regimens, expanding deployment of advanced diagnostic tools, advancing integration of ai-powered treatment monitoring.

The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to drive the growth of the nontuberculous mycobacterial (NTM) infection market in the coming years. COPD is a progressive respiratory disorder characterized by persistent airflow limitation, often leading to weakened lung function and increased vulnerability to infections. Patients with COPD are at higher risk of NTM infections, which are associated with accelerated decline in forced expiratory volume in one second (FEV₁) and increased exacerbation rates. For instance, in September 2024, Public Health Scotland reported that in 2022/23, the incidence of COPD in Scotland was 112.4 cases per 100,000 for females and 109.7 cases per 100,000 for males, highlighting the significant disease burden. Consequently, the growing prevalence of COPD is fueling demand for effective NTM infection management.

Major companies in the NTM infection market are concentrating on advanced solutions, such as boron-based antibiotics, to improve treatment efficacy and tackle drug-resistant infections. Boron-based antibiotics are small-molecule therapies that inhibit bacterial protein synthesis, offering potent and safer options for persistent infections. For example, in September 2023, AN2 Therapeutics, a US-based biopharmaceutical company, initiated enrollment in the Phase 3 portion of its pivotal Phase 2/3 trial for epetraborole in treatment-refractory Mycobacterium avium complex lung disease. Designed for oral administration, epetraborole showed promising preclinical results for Mycobacterium abscessus infections, aiming to reduce treatment duration, improve tolerability, and address unmet medical needs in rare infectious lung diseases.

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, partnered with TB Alliance to develop telacebec for tuberculosis and other NTM infections. Under this collaboration, TB Alliance received the exclusive global license to advance and commercialize telacebec worldwide. TB Alliance, a South Africa-based non-profit organization, focuses on developing and delivering affordable tuberculosis treatments, reflecting a strategic effort to expand access to therapies for NTM and related infectious diseases.

Major companies operating in the nontuberculous mycobacterial infection market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.

North America was the largest region in the nontuberculous mycobacterial infection market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the nontuberculous mycobacterial infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nontuberculous mycobacterial infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the nontuberculous mycobacterial infection market by increasing the cost of imported antibiotics, aminoglycosides, rifampin, and advanced diagnostic devices. Hospital pharmacies, retail pharmacies, and online pharmacy segments are most affected, with north america, europe, and asia-pacific facing significant cost pressures. While tariffs raise procurement costs and delay access, they also encourage local manufacturing, drive innovation in cost-effective drug formulations, and strengthen domestic healthcare supply chains.

The nontuberculous mycobacterial infection market research report is one of a series of new reports that provides nontuberculous mycobacterial infection market statistics, including nontuberculous mycobacterial infection industry global market size, regional shares, competitors with a nontuberculous mycobacterial infection market share, detailed nontuberculous mycobacterial infection market segments, market trends and opportunities, and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. This nontuberculous mycobacterial infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A nontuberculous mycobacterial (NTM) infection is caused by various mycobacteria species other than *Mycobacterium tuberculosis*, the bacterium responsible for tuberculosis (TB). NTM infections are significant due to their effects on human health and their interaction with the immune system.

The main drug classes used to treat nontuberculous mycobacterial infections include macrolides, rifampin, aminoglycosides, and others. Macrolides are a group of antibiotics commonly prescribed for a range of bacterial infections. They can be administered orally, parenterally, and via other routes, and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.